Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment
for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can
significantly impact a patient's quality of life and ability to tolerate chemo/anti-HER2
therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea
in breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Georgetown University
Collaborators:
Genentech, Inc. Lombardi Comprehensive Cancer Center Medstar Health Research Institute Napo Pharmaceuticals, Inc.